At the time of writing, Integra Lifesciences Holdings Corp [IART] stock is trading at $34.61, up 0.49%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IART shares have gain 3.25% over the last week, with a monthly amount drifted -5.77%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, April 2024, Integra LifeSciences Completes the Acquisition of Acclarent, Inc. In a post published today on Yahoo Finance, Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent’s innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel. The acquisition adds $1 billion to the total addressable market of the Company’s offerings, while providing unique market opportunities for access to the attractive ENT device segment.
From an analyst’s perspective:
Integra Lifesciences Holdings Corp [NASDAQ: IART] stock has seen the most recent analyst activity on April 03, 2024, when Citigroup upgraded its rating to a Neutral but kept the price target unchanged to $38 for it. Previously, Wells Fargo upgraded its rating to Overweight on December 05, 2023, and elevated its price target to $49. On November 14, 2023, CL King initiated with a Buy rating and assigned a price target of $50 on the stock. Morgan Stanley downgraded its rating to a Underweight but stick to its price target of $44 on August 24, 2023. Jefferies upgraded its rating to a Buy and reduced its price target to $53 on July 12, 2023. Argus downgraded its rating to Hold for this stock on June 08, 2023. In a note dated May 24, 2023, JP Morgan downgraded an Underweight rating on this stock and revised its target price from $56 to $43.
For the past year, the stock price of Integra Lifesciences Holdings Corp fluctuated between $33.24 and $59.33. Currently, Wall Street analysts expect the stock to reach $71 within the next 12 months. Integra Lifesciences Holdings Corp [NASDAQ: IART] shares were valued at $34.61 at the most recent close of the market. An investor can expect a potential return of 105.14% based on the average IART price forecast.
Analyzing the IART fundamentals
According to Integra Lifesciences Holdings Corp [NASDAQ:IART], the company’s sales were 1.54B for trailing twelve months, which represents an -0.25% plunge. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.04 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.95.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.40 points at the first support level, and at 34.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 34.80, and for the 2nd resistance point, it is at 35.00.
Integra Lifesciences Holdings Corp [IART] reported earnings per share of $0.89 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.9/share, meaning a difference of -$0.01 and a surprise factor of -1.10%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.76 per share as compared to estimates of $0.78 per share, a difference of -$0.02 representing a surprise of -2.60%.
Ratios To Look Out For
It is important to note that Integra Lifesciences Holdings Corp [NASDAQ:IART] has a current ratio of 3.45. Further, the Quick Ratio stands at 2.18, while the Cash Ratio is 0.9. Considering the valuation of this stock, the price to sales ratio is 1.76, the price to book ratio is 1.70 and price to earnings (TTM) ratio is 41.04.
Transactions by insiders
Recent insider trading involved DAVIS ROBERT T. JR., EVP & President, TT, that happened on Mar 06 ’24 when 8348.0 shares were sold. SVP, Fin & PAO, Mosebrook Jeffrey completed a deal on Aug 09 ’23 to sell 1177.0 shares. Meanwhile, President & CEO De Witte Jan bought 7792.0 shares on Jun 01 ’23.
